Calmark enters into cooperation with VIA Global Health to accelerate globalization

Calmark Sweden AB today announced that an agreement regarding distribution of the Company's products has been signed with the U.S. company VIA Global Health, which specializes in distribution of medical devices in low- and middle-income countries. The agreement entails that Calmark's products can reach out to countries in, e.g., Africa and South America sooner than anticipated, and more cost-efficiently.

VIA Global Health has a world class e-commerce procurement and distribution platform to serve low-and middle-income countries with life-saving medical technologies, with the goal of  universal access to critical medical products, information, services, and life-saving medical equipment to underserved communities. The company has received support from the Bill and Melinda Gates Foundation to support its efforts in expanding distribution of maternal and newborn health products. By providing a link to smaller distributors in low- and middle-income countries, products can reach parts of the world that usually are not included in companies' launch plans. VIA Global Health has delivered products to over 70 countries and offers a number of important products for maternal and child care as well as COVID-19-related products.

"Calmark's products for newborn infants fit very well within our product portfolio; point of care solutions like those developed by Calmark are in great need in countries where the health care systems are resource constrained. The products will soon be available for global order on our website and we will support our customers with training and logistics to access these products. We very much look forward to collaborating with Calmark," says Brinnon Mandel, Vice President of Market Insights, VIA Global Health.

"VIA Global Health has a unique network in those countries where our product promises to deliver the most significant benefits. For us, this cooperation is an important step towards fulfilling our mission to reduce infant mortality before 2030. VIA Global Health is a greatly appreciated company that has received considerable attention. It has a big heart, and we are exceedingly proud to have the opportunity to work with it," says Anna Söderlund, CEO of Calmark.

Read more about VIA Global Health: https://viaglobalhealth.com/

This information is information that Calmark Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09:25 CET on 26 November 2020.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.